Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer.

Current oncology (Toronto, Ont.) - 26 Dec 2022

Avilés-Salas Alejandro, Díaz-García Diego A, Lara-Mejía Luis, Cardona Andrés F, Orozco-Morales Mario, Catalán Rodrigo, Hernández-Pedro Norma Y, Rios-Garcia Eduardo, Ramos-Ramírez Maritza, Arrieta Oscar

Abstract excerpt

(1) Background: Liver kinase B1 (LKB1) is a tumor suppressor gene involved in cell growth and metabolism. However, its alterations are not routinely assessed for guiding therapy in clinical practice. We assessed LKB1 expression by immunohistochemistry as a potential biomarker. (2) Methods: This bicentric retrospective cohort study analyzed data from patients with advanced NSCLC who initiated platinum-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunohistochemistry

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Staging

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 36661676
DOI: 10.3390/curroncol30010027
PMCID: PMC9857995

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer.PMID 36661676Read ↗

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact.Semantic proximity Read ↗

LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.Semantic proximity Read ↗

Expression profiling of ubiquitin-related genes in LKB1 mutant lung adenocarcinoma.Semantic proximity Read ↗

Clinicopathologic correlations of liver kinase B1, E-cadherin, and N-cadherin expression in non-small cell lung cancer.Semantic proximity Read ↗

Genetic and epigenetic alterations of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean non-small cell lung cancers.Semantic proximity Read ↗

Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Semantic proximity Read ↗

Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers.Semantic proximity Read ↗

A transcriptional signature of LKB1 functional loss defines a large, therapeutically addressable patient population across human cancersSemantic proximity Read ↗

Loss of FGL1 induces epithelial‑mesenchymal transition and angiogenesis in LKB1 mutant lung adenocarcinomaSemantic proximity Read ↗

LKB1 modulates lung cancer differentiation and metastasisSemantic proximity Read ↗

Cytoplasmic liver kinase B1 promotes the growth of human lung adenocarcinoma by enhancing autophagySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.